MigraineMind research summary

Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group.

Front Neurol | 2026

Observational study
AuthorsRikos D, Argyriou AA, Dermitzakis EV, Soldatos P, Dimisianos N
JournalFront Neurol
Publication year2026
PubMed ID42591283

Summary

This study explored how effective and safe a combination of sumatriptan and naproxen is for treating migraines. The research involved 111 patients who experienced multiple migraine attacks. Each patient received the combination treatment during these attacks. The main goal was to see how many patients felt pain relief within two hours. Results showed that 23.8% of attacks resulted in complete pain freedom after two hours. In 68.8% of cases, patients reported some pain relief within the same time frame. The study also looked at how long the relief lasted and if patients could return to normal activities. Patients experienced some side effects, but they were generally mild. Overall, the combination of sumatriptan and naproxen was found to be a useful option for many patients suffering from migraines, with a good safety profile. Clinical relevance: This research indicates that the sumatriptan and naproxen combination may provide effective relief for migraine sufferers, enhancing treatment options for acute migraine management.

Related migraine research topics

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.